Balantidiasis Market Gains Momentum with a Striking CAGR of 2.1% by 2023

The global balantidiasis market is expected to grow at a CAGR of 2.1% during the forecast period.

Balantidiasis, also known as Balantidium coli infection, is a disease caused by intestinal protozoan parasite Balantidium coli. Being transmitted through the fecal-oral route, a person acquires the disease by ingesting infective cysts from food and water contaminated by feces. The global Balantidiasis Market is growing steadily and is expected to continue its growth during the forecast period.

Get a Sample Report @ https://www.marketresearchfuture.com/sample_request/4725 .

The disease mainly affects large intestine. Diarrhea, weight loss, dysentery, abdominal pain, nausea, and vomiting are common symptoms for balantidiasis. The diseases is found to be prevalent in the rural areas of the developed and developing countries due to the contamination of water by the fecal matter of pigs or humans. The best remedy for the prevention of the disease are maintaining proper conditions for clean and safe drinking water. Antibiotics are most widely used for the treatment of balantidiasis.

Rising prevalence of gastrointestinal disorders, increasing number of patients and availability of treatment of balantidiasis drives the growth of the market. Additionally, the lack of hygiene and sanitation in the rural areas of developing countries is one of the many factors which affect the spread of this disease. Furthermore, rising awareness about the diseases transmitted through fecal-oral route influences the market growth. Competition among existing market players restrict the entry of new players.

Top Key Players of this Market:

Some of the key players in this market are Pfizer (U.S.), Abbott (U.S.), GlaxoSmithKline plc. (U.K), BD (U.S.), Sandoz International GmbH (Germany), Amneal Pharmaceuticals LLC. (U.S.), Akorn, Inc. (U.S.), and PharmaDerm, a division of Fougera Pharmaceuticals Inc. (U.S.).

Regional Analysis of the Global Balantidiasis Market:

The Balantidiasis Industry is found to be steady in Americas. The disease is less prevalent in North America due to high quality standards, negligible number of cases, and hygienic environment. Furthermore, emphasis on healthy life style and prevention of communicable diseases also influence the growth of the market. The prevalence of the disease is found to the higher rural South America than North American countries.

In Europe, the prevalence of balantidiasis is found to be low. Rising importance of hygienic food products and water, rigorous quality checks, rising expenditure on healthcare, and availability of funds boost the growth of the market.

In Asia Pacific, the prevalence of balantidiasis is found increasing steadily as a result of increasing prevalence of colitis, chronic diarrhea, and, deep intestinal ulcerations and poor hygienic conditions in developing countries. The infection is found to be sub clinical leading to the development of diarrhea leading to the perforation of colon. Furthermore, poor healthcare system in developing countries boost the market growth. Furthermore, the burden of gastrointestinal diseases is attributed to an increase in age, high prevalence of H pylori and lifestyle changes with risk factors such as smoking and obesity. According to the data from GLOBOCAN, in 2012, the age-standardized rate (ASR) of incidence for Asia Pacific was 15.8 and mortality was 11.7 per 100,000. According to World Health Organization (WHO), the geriatric population in China in the year 2013 was 22.6 million which is expected to show a massive growth to 90.4 million in 2050.

Apply for Discount @ https://www.marketresearchfuture.com/check-discount/4725 .

The Middle East & African region has high prevalence of balantidiasis. The infection is mainly acquired due to ingestion of food and water contaminated by cysts. Furthermore, gastrointestinal diseases are a major cause of disability in the Middle East & Africa. In Africa, the market for balantidiasis is driven by rising demand for primary care services and improving healthcare system.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:
Akash Anand,
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.